Depot-medroxyprogesterone acetate (DMPA) and cancer: Memorandum from a WHO meeting

C. Supawat, R. Gray, C. Hill, B. Hulka

Research output: Contribution to journalReview articlepeer-review


A review of all available data including those from the WHO Collaborative Study of Neoplasia and Steroid Contraceptives has shown no increased risk of cancers of the breast, endometrium, ovary or liver in women using depot-medroxyprogesterone acetate (DMPA). The issue of a causal association between DMPA use and cervical cancer is as yet unresolved and will require the accumulation of additional data. To date, in the WHO study only a small number of women have used DMPA for prolonged periods or have had a long interval since first use. Information on cancer risk in these women can only be gained by continuing the present study or by initiating additional studies focused on these specific topics.

Original languageEnglish (US)
Pages (from-to)375-382
Number of pages8
JournalBulletin of the World Health Organization
Issue number3
StatePublished - 1986
Externally publishedYes

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health


Dive into the research topics of 'Depot-medroxyprogesterone acetate (DMPA) and cancer: Memorandum from a WHO meeting'. Together they form a unique fingerprint.

Cite this